

AMENDED IN SENATE JULY 15, 2010

AMENDED IN SENATE JUNE 17, 2010

AMENDED IN ASSEMBLY JANUARY 25, 2010

AMENDED IN ASSEMBLY JANUARY 6, 2010

AMENDED IN ASSEMBLY JANUARY 4, 2010

AMENDED IN ASSEMBLY APRIL 21, 2009

AMENDED IN ASSEMBLY APRIL 14, 2009

CALIFORNIA LEGISLATURE—2009—10 REGULAR SESSION

ASSEMBLY BILL

No. 549

Introduced by Assembly Member Furutani

February 25, 2009

An act to amend Sections 1206, 1207, 1209.1, 1264, and 1300 of, and to add Sections 1263.5 and 1264.5 to, the Business and Professions Code, relating to healing arts.

LEGISLATIVE COUNSEL'S DIGEST

AB 549, as amended, Furutani. Licensure: clinical laboratory personnel.

Existing law provides for the regulation and licensure of clinical laboratories and clinical laboratory personnel by the State Department of Public Health. Existing law requires the department to issue a clinical chemist, clinical microbiologist, clinical toxicologist, clinical molecular biologist, or clinical cytogeneticist license to each person who has applied for the license on a specified form, who also holds a master of science or doctoral degree in the specialty for which the applicant is

seeking a license, and who has met other requirements, including the payment of specified application and license fees. Existing law requires the department to determine by examination, except as specified, whether an applicant is qualified. Existing law requires the graduate education to have included 30 semester hours of coursework in the applicants's specialty.

This bill would require the department to issue a clinical biochemical geneticist license to a person meeting these requirements in the subspecialty of biochemical genetics, as defined. For the above-enumerated specialties and subspecialties, the bill would specify that a formal letter or other official written documentation issued by an accredited training program indicating that an applicant completed the program, and from a clinical laboratory confirming the applicant's employment experience, shall constitute sufficient evidence. The bill would also require an applicant to provide evidence of satisfactory performance on a written examination in the applicant's specialty or subspecialty administered by an appropriate accrediting body recognized by the department.

This bill would require the department to post application forms and instructions for licensure in clinical laboratory practice on its Internet Web site, to notify an applicant, within 30 days of filing, whether the application is complete or requires additional documentation to become complete, and to process each completed application within 90 days. The bill would specify periods of eligibility for an applicant to take a required examination. The bill would also require the department to issue a temporary license to an applicant meeting specified experience and certification requirements, within 30 days of receiving a completed application. The bill would also make conforming changes.

Existing law requires the department to license as trainees those individuals desiring to train for a clinical laboratory scientist's license or a limited clinical laboratory scientist's license, provided those individuals meet certain academic requirements.

This bill would require the department to adopt emergency regulations creating a trainee license in enumerated specialties and subspecialties for applicants who meet specified requirements.

Vote: majority. Appropriation: no. Fiscal committee: yes.
State-mandated local program: no.

The people of the State of California do enact as follows:

SECTION 1. Section 1206 of the Business and Professions Code is amended to read:

1206. (a) For the purposes of this chapter the following definitions are applicable:

(1) "Biological specimen" means any material that is derived from the human body.

(2) "Blood electrolyte analysis" means the measurement of electrolytes in a blood specimen by means of ion selective electrodes on instruments specifically designed and manufactured for blood gas and acid-base analysis.

(3) "Blood gas analysis" means a clinical laboratory test or examination that deals with the uptake, transport, and metabolism of oxygen and carbon dioxide in the human body.

(4) "Clinical laboratory test or examination" means the detection, identification, measurement, evaluation, correlation, monitoring, and reporting of any particular analyte, entity, or substance within a biological specimen for the purpose of obtaining scientific data which may be used as an aid to ascertain the presence, progress, and source of a disease or physiological condition in a human being, or used as an aid in the prevention, prognosis, monitoring, or treatment of a physiological or pathological condition in a human being, or for the performance of nondiagnostic tests for assessing the health of an individual.

(5) "Clinical laboratory science" means any of the sciences or scientific disciplines used to perform a clinical laboratory test or examination.

(6) "Clinical laboratory practice" means the application of clinical laboratory sciences or the use of any means that applies the clinical laboratory sciences within or outside of a licensed or registered clinical laboratory. Clinical laboratory practice includes consultation, advisory, and other activities inherent to the profession.

(7) "Clinical laboratory" means any place used, or any establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences.

(8) “Direct and constant supervision” means personal observation and critical evaluation of the activity of unlicensed laboratory personnel by a physician and surgeon, or by a person licensed under this chapter other than a trainee, during the entire time that the unlicensed laboratory personnel are engaged in the duties specified in Section 1269.

(9) “Location” means either a street and city address, or a site or place within a street and city address, where any of the clinical laboratory sciences or scientific disciplines are practiced or applied, or where any clinical laboratory tests or examinations are performed.

(10) “Physician office laboratory” means a clinical laboratory that is licensed or registered under Section 1265, and that is either: (A) a clinical laboratory that is owned and operated by a partnership or professional corporation that performs clinical laboratory tests or examinations only for patients of five or fewer physicians and surgeons or podiatrists who are shareholders, partners, or employees of the partnership or professional corporation that owns and operates the clinical laboratory; or (B) a clinical laboratory that is owned and operated by an individual licensed physician and surgeon or a podiatrist, and that performs clinical laboratory tests or examinations only for patients of the physician and surgeon or podiatrist who owns and operates the clinical laboratory.

(11) “Public health laboratory” means a laboratory that is operated by a city or county in conformity with Article 5 (commencing with Section 101150) of Chapter 2 of Part 3 of Division 101 of the Health and Safety Code and the regulations adopted thereunder.

(12) “Specialty” means histocompatibility, microbiology, diagnostic immunology, chemistry, hematology, immunochemistry, pathology, genetics, or other specialty specified by regulation adopted by the department.

(13) “Subspecialty” for purposes of microbiology, means bacteriology, mycobacteriology, mycology, parasitology, virology, molecular biology, and serology for diagnosis of infectious diseases, or other subspecialty specified by regulation adopted by the department; for purposes of diagnostic immunology, means syphilis serology, general immunology, or other subspecialty specified by regulation adopted by the department; for purposes of chemistry, means routine chemistry, clinical microscopy,

1 endocrinology, toxicology, or other subspecialty specified by
2 regulation adopted by the department; for purposes of
3 immunohematology, means ABO/Rh Type and Group, antibody
4 detection for transfusion, antibody detection nontransfusion,
5 antibody identification, compatibility, or other subspecialty
6 specified by regulation adopted by the department; for pathology,
7 means tissue pathology, oral pathology, diagnostic cytology, or
8 other subspecialty specified by regulation adopted by the
9 department; for purposes of genetics, means molecular biology
10 related to the diagnosis of human genetic abnormalities,
11 biochemical genetics, cytogenetics, or other subspecialty specified
12 by regulation adopted by the department.

13 (14) “Biochemical genetics” means techniques used to analyze
14 human proteins and certain metabolites from physiological samples
15 for the primary purpose of detecting inborn errors of metabolism,
16 heritable genotypes or gene products of genetic variations or
17 mutations for clinical purposes that include, but are not limited to,
18 the use of these test results to aid in the evaluation and diagnosis
19 of patients, predicting risk of disease, identifying carriers, and
20 establishing prenatal or clinical diagnoses or prognoses in
21 individuals, families, and populations.

22 (15) “Direct and responsible supervision” means both of the
23 following:

24 (A) Personal observation and critical evaluation of the activity
25 of a trainee by a physician and surgeon, or by a person licensed
26 under this chapter other than a trainee, during the entire time that
27 the trainee is performing clinical laboratory tests or examinations.

28 (B) Personal review by the physician and surgeon or the licensed
29 person of all results of clinical laboratory testing or examination
30 performed by the trainee for accuracy, reliability, and validity
31 before the results are reported from the laboratory.

32 (16) “Licensed laboratory” means a clinical laboratory licensed
33 pursuant to paragraph (1) of subdivision (a) of Section 1265.

34 (17) “Registered laboratory” means a clinical laboratory
35 registered pursuant to paragraph (2) of subdivision (a) of Section
36 1265.

37 (18) “Point-of-care laboratory testing device” means a portable
38 laboratory testing instrument to which the following applies:

39 (A) It is used within the proximity of the patient for whom the
40 test or examination is being conducted.

1 (B) It is used in accordance with the patient test management
2 system, the quality control program, and the comprehensive quality
3 assurance program established and maintained by the laboratory
4 pursuant to paragraph (2) of subdivision (d) of Section 1220.

5 (C) It meets the following criteria:

6 (i) Performs clinical laboratory tests or examinations classified
7 as waived or of moderate complexity under CLIA.

8 (ii) Performs clinical laboratory tests or examinations on
9 biological specimens that require no preparation after collection.

10 (iii) Provides clinical laboratory tests or examination results
11 without calculation or discretionary intervention by the testing
12 personnel.

13 (iv) Performs clinical laboratory tests or examinations without
14 the necessity for testing personnel to perform calibration or
15 maintenance, except resetting pursuant to the manufacturer's
16 instructions or basic cleaning.

17 (19) "Analyte" means the substance or constituent being
18 measured, including, but not limited to, glucose, sodium, or
19 theophylline, or any substance or property whose presence or
20 absence, concentration, activity, intensity, or other characteristics
21 are to be determined.

22 (b) Nothing in this chapter shall restrict, limit, or prevent any
23 person licensed to provide health care services under the laws of
24 this state, including, but not limited to, licensed physicians and
25 surgeons and registered nurses, from practicing the profession or
26 occupation for which he or she is licensed.

27 (c) Nothing in this chapter shall authorize any person to perform
28 or order health care services, or utilize the results of the clinical
29 laboratory test or examination, unless the person is otherwise
30 authorized to provide that care or utilize the results. The inclusion
31 of a person in Section 1206.5 for purposes of performing a clinical
32 laboratory test or examination shall not be interpreted to authorize
33 a person, who is not otherwise authorized, to perform venipuncture,
34 arterial puncture, or skin puncture.

35 SEC. 2. Section 1207 of the Business and Professions Code is
36 amended to read:

37 1207. (a) As used in this chapter, "clinical chemist," or
38 "clinical microbiologist," or "clinical toxicologist," or "clinical
39 genetic molecular biologist," or "clinical biochemical geneticist,"
40 or "clinical cytogeneticist," or "oral and maxillofacial pathologist"

1 means any person licensed by the department under Section 1264
2 to engage in, or supervise others engaged in, clinical laboratory
3 practice limited to his or her area of specialization or to direct a
4 clinical laboratory, or portion thereof, limited to his or her area of
5 specialization. Such a licensed person who is qualified under CLIA
6 may perform clinical laboratory tests or examinations classified
7 as of high complexity under CLIA, and the duties and
8 responsibilities of a laboratory director, technical consultant,
9 clinical consultant, technical supervisor, and general supervisor,
10 as specified under CLIA, limited to his or her area of specialty or
11 subspecialty as described in subdivision (b), and shall only direct
12 a clinical laboratory providing service within those specialties or
13 subspecialties. A person licensed as a “clinical chemist,” or
14 “clinical microbiologist,” or “clinical toxicologist,” or “clinical
15 genetic molecular biologist,” or “clinical biochemical geneticist,”
16 or “clinical cytogeneticist,” or “oral and maxillofacial pathologist”
17 may perform any clinical laboratory test or examination classified
18 as waived or of moderate complexity under CLIA.

19 (b) The specialty or subspecialty for each of the limited license
20 categories identified in subdivision (a), and the clinical laboratories
21 that may be directed by persons licensed in each of those
22 categories, are the following:

23 (1) For a person licensed under this chapter as a clinical chemist,
24 the specialty of chemistry and the subspecialties of routine
25 chemistry, endocrinology, clinical microscopy, toxicology, or other
26 specialty or subspecialty specified by regulation adopted by the
27 department.

28 (2) For a person licensed under this chapter as a clinical
29 microbiologist, the specialty of microbiology and the subspecialties
30 of bacteriology, mycobacteriology, mycology, parasitology,
31 virology, molecular biology, and serology for diagnosis of
32 infectious diseases, or other specialty or subspecialty specified by
33 regulation adopted by the department.

34 (3) For a person licensed under this chapter as a clinical
35 toxicologist, the subspecialty of toxicology within the specialty of
36 chemistry or other specialty or subspecialty specified by regulation
37 adopted by the department.

38 (4) For a person licensed under this chapter as a clinical genetic
39 molecular biologist, the subspecialty of molecular biology related
40 to diagnosis of human genetic abnormalities within the specialty

1 of genetics or other specialty or subspecialty specified by regulation
2 adopted by the department.

3 (5) For a person licensed under this chapter as a clinical
4 cytogeneticist, the subspecialty of cytogenetics within the specialty
5 of genetics or other specialty or subspecialty specified by regulation
6 adopted by the department.

7 (6) For a person licensed under this chapter as an oral and
8 maxillofacial pathologist, the subspecialty of oral pathology within
9 the specialty of pathology or other specialty or subspecialty
10 specified by regulation adopted by the department.

11 (7) For a person licensed under this chapter as a clinical
12 biochemical geneticist, the subspecialty of biochemical genetics
13 within the specialty of genetics or other specialty or subspecialty
14 specified by regulation adopted by the department.

15 SEC. 3. Section 1209.1 of the Business and Professions Code
16 is amended to read:

17 1209.1. (a) As used in this chapter, “histocompatibility
18 laboratory director” means a physician and surgeon licensed to
19 practice medicine pursuant to Chapter 5 (commencing with Section
20 2000) who is qualified pursuant to Section 1209, a bioanalyst
21 licensed pursuant to Section 1260 who is qualified pursuant to
22 Sections 1203 and 1209, or a person who has earned a doctoral
23 degree in a biological science, who has completed, subsequent to
24 graduation, four years of experience in immunology, two of which
25 have been in histocompatibility testing.

26 (b) On and after January 1, 2007, in order to be eligible for
27 licensure as a histocompatibility laboratory director, an applicant
28 who is not a duly licensed physician and surgeon or a duly licensed
29 bioanalyst shall provide evidence of satisfactory performance on
30 a written examination in histocompatibility administered by the
31 American Board of Histocompatibility and Immunogenetics, and
32 have demonstrated satisfactory performance on an oral examination
33 administered by the department regarding this chapter and Part
34 493 (commencing with Section 493.1) of Subchapter G of Chapter
35 IV of Title 42 of the Code of Federal Regulations.

36 (c) A person licensed under Section 1260.1 as a
37 histocompatibility laboratory director and qualified under CLIA
38 may perform clinical laboratory tests or examinations classified
39 as of high complexity under CLIA and the duties and
40 responsibilities of a laboratory director, technical consultant,

1 clinical consultant, technical supervisor, and general supervisor,
2 as specified under CLIA, in the specialty of histocompatibility,
3 immunology, or other specialty or subspecialty specified by
4 regulation adopted by the department. A person licensed as a
5 “histocompatibility laboratory director” may perform any clinical
6 laboratory test or examination classified as waived or of moderate
7 complexity under CLIA.

8 (d) The department shall, within 30 days of receiving a
9 completed application, issue a temporary license to any applicant
10 seeking licensure pursuant to this section, provided that the
11 applicant meets the following requirements:

12 (1) The applicant has at least two years of experience as a
13 histocompatibility laboratory director in another state of the United
14 States or in Canada.

15 (2) The applicant has board certification from the American
16 Board of Histocompatibility and Immunogenetics.

17 (e) A temporary license issued pursuant to subdivision (d) shall
18 remain valid until the department completes evaluating and
19 processing the applicant’s completed application, the applicant
20 has passed any required examinations, and the department has
21 issued a permanent license. If the applicant fails to pass the required
22 examinations, the department may revoke the temporary license
23 upon notice to the applicant sent by first-class mail.

24 SEC. 4. Section 1263.5 is added to the Business and Professions
25 Code, to read:

26 1263.5. The department shall, no later than April 1, 2011, adopt
27 emergency regulations creating a trainee license in clinical
28 chemistry, clinical microbiology, clinical toxicology, clinical
29 molecular biology, clinical biochemical genetics, and clinical
30 cytogenetics, and as a clinical histocompatibility and immunology
31 laboratory director for applicants holding an earned doctoral degree
32 in a biological science or field related to genetics from an
33 accredited university and who provide evidence of satisfactory
34 performance on a written examination in the area of specialty that
35 is administered by the American Board of Medical Genetics, the
36 Canadian Council of Medical Genetics, or the appropriate
37 accrediting body for the area of specialty for which the applicant
38 is seeking licensure. The adoption of these emergency regulations
39 shall be considered by the Office of Administrative Law to be

1 necessary to avoid serious harm to the public health, safety, or
2 general welfare.

3 SEC. 5. Section 1264 of the Business and Professions Code is
4 amended to read:

5 1264. The department shall issue a clinical chemist, clinical
6 microbiologist, clinical toxicologist, clinical molecular biologist,
7 clinical biochemical geneticist, or clinical cytogeneticist license
8 to each person who has applied for the license on forms provided
9 by the department, who is a lawful holder of a master of science
10 or doctoral degree in the specialty for which the applicant is
11 seeking a license, and who has met such additional reasonable
12 qualifications of training, education, and experience as the
13 department may establish by regulations. The department shall
14 issue an oral and maxillofacial pathologist license to every
15 applicant for licensure who has applied for the license on forms
16 provided by the department, who is a registered Diplomate of the
17 American Board of Oral and Maxillofacial Pathology, and who
18 meets any additional and reasonable qualifications of training,
19 education, and experience as the department may establish by
20 regulation.

21 (a) (1) Unless otherwise required by regulation, the graduate
22 education shall have included 30 semester hours of coursework in
23 the applicant's specialty. Applicants possessing only a master of
24 science degree shall have the equivalent of one year of full-time,
25 directed study or training in procedures and principles involved
26 in the development, modification, or evaluation of laboratory
27 methods, including training in complex methods applicable to
28 diagnostic laboratory work. Each applicant must have had one
29 year of training in his or her specialty in a clinical laboratory
30 acceptable to the department and three years of experience in his
31 or her specialty in a clinical laboratory, two years of which must
32 have been at a supervisory level. The education shall have been
33 obtained in one or more established and reputable institutions
34 maintaining standards equivalent, as determined by the department,
35 to those institutions accredited by an agency acceptable to the
36 department. The department shall determine by examination that
37 the applicant is properly qualified. Examinations, training, or
38 experience requirements for specialty licenses shall cover only the
39 specialty concerned.

(2) A formal letter or other official written documentation issued by an accredited training program indicating that the applicant has completed the program, and from a clinical laboratory or laboratories confirming the applicant's employment experience as required by regulation, shall constitute sufficient evidence for the purpose of this subdivision. Each applicant shall also provide evidence of satisfactory performance on a written examination in the applicant's specialty or subspecialty administered by an appropriate accrediting body recognized by the department. In order to constitute sufficient evidence for this purpose, formal letters or other documentation required by this paragraph shall be provided directly by the examining agency or appropriate accrediting body to the department.

(b) The department may issue licenses without the examination required by paragraph (1) of subdivision (a) to applicants who have passed examinations of other states or an appropriate accrediting body whose requirements are equal to or greater than those required by this chapter and regulations established by the department. The evaluation of other state requirements or requirements of appropriate accrediting bodies shall be carried out by the department with the assistance of representatives from the licensed groups. This section shall not apply to persons who have passed an examination by another state or appropriate accrediting body prior to the establishment of requirements that are equal to or exceed those of this chapter or regulations of the department.

(c) The department may issue licenses without examination to applicants who had met standards of education and training, defined by regulations, prior to the date of the adoption of implementing regulations.

(d) The department shall, within 30 days of receiving a completed application, issue a temporary license to any applicant seeking licensure pursuant to this section, provided that the applicant meets the following requirements:

(1) The applicant has at least two years of experience as a licensed clinical chemist, clinical microbiologist, clinical toxicologist, clinical molecular biologist, clinical biochemical geneticist, or clinical cytogeneticist in another state of the United States or in Canada and the applicant's license remains in good standing.

1 (2) The applicant has board certification from an appropriate
2 ~~accrediting~~ body recognized by ~~CLIA~~ *the United States Department*
3 *of Health and Human Services* in the area of specialty or
4 subspecialty for which he or she is seeking licensure.

5 (e) A temporary license issued pursuant to subdivision (d) shall
6 remain valid until the department completes the evaluation and
7 processing of the applicant's completed application, the applicant
8 has passed each required examination, and the department has
9 issued a permanent license. If the applicant fails to pass a required
10 examination, the department may revoke the temporary license
11 upon notice sent to the applicant by first-class mail.

12 (f) The department shall adopt regulations to conform to this
13 section.

14 SEC. 6. Section 1264.5 is added to the Business and Professions
15 Code, to read:

16 1264.5. (a) The department shall maintain an expeditious
17 process for licensing applicants for licensure in clinical laboratory
18 practice. Application forms and instructions for each category of
19 licensure shall be posted on the department's Internet Web site.

20 (b) Within 30 calendar days after receiving an application for
21 licensure in clinical laboratory practice, including a resubmission
22 of an application, the department shall notify the applicant in
23 writing or by electronic mail that the application is complete and
24 shall be processed by the department or that the application is
25 incomplete. If the application is incomplete, the department shall
26 specify in the notification the transcripts, board certification,
27 verification of training, or other documents required to complete
28 the application for licensure that have not been received by the
29 department.

30 (c) The department shall process each completed application
31 within 90 calendar days following receipt of the completed
32 application.

33 (d) An applicant for licensure in clinical laboratory practice
34 shall be eligible for any required examinations upon notification
35 by the department that the applicant's application has been
36 approved. An applicant shall be eligible for the required
37 examinations for 180 calendar days following the date eligibility
38 begins. Eligibility shall be extended for an additional 180 calendar
39 days if a required examination has not been offered or scheduled
40 by the department within the original 180-day period.

SEC. 7. Section 1300 of the Business and Professions Code is amended to read:

1300. The amount of application, registration, and license fees under this chapter shall be as follows:

(a) The application fee for a histocompatibility laboratory director's, clinical laboratory bioanalyst's, clinical chemist's, clinical microbiologist's, clinical laboratory toxicologist's, clinical biochemical geneticist's, clinical cytogeneticist's, or clinical molecular biologist's license is sixty-three dollars (\$63) commencing on July 1, 1983.

(b) The annual renewal fee for a histocompatibility laboratory director's, clinical laboratory bioanalyst's, clinical chemist's, clinical microbiologist's, clinical laboratory toxicologist's, or clinical biochemical geneticist's license is sixty-three dollars (\$63) commencing on July 1, 1983.

(c) The application fee for a clinical laboratory scientist's or limited clinical laboratory scientist's license is thirty-eight dollars (\$38) commencing on July 1, 1983.

(d) The application and annual renewal fee for a cytotechnologist's license is fifty dollars (\$50) commencing on January 1, 1991.

(e) The annual renewal fee for a clinical laboratory scientist's or limited clinical laboratory scientist's license is twenty-five dollars (\$25) commencing on July 1, 1983.

(f) A clinical laboratory applying for a license to perform tests or examinations classified as of moderate or of high complexity under CLIA and a clinical laboratory applying for certification under subdivision (c) of Section 1223 shall pay an application fee for that license or certification based on the number of tests it performs or expects to perform in a year, as follows:

(1) Less than 2,001 tests: two hundred seventy dollars (\$270).

(2) Between 2,001 and 10,000, inclusive, tests: eight hundred twenty dollars (\$820).

(3) Between 10,001 and 25,000, inclusive, tests: one thousand three hundred fifteen dollars (\$1,315).

(4) Between 25,001 and 50,000, inclusive, tests: one thousand five hundred eighty dollars (\$1,580).

(5) Between 50,001 and 75,000, inclusive, tests: one thousand nine hundred sixty dollars (\$1,960).

- 1 (6) Between 75,001 and 100,000, inclusive, tests: two thousand
2 three hundred forty dollars (\$2,340).
- 3 (7) Between 100,001 and 500,000, inclusive, tests: two thousand
4 seven hundred forty dollars (\$2,740).
- 5 (8) Between 500,001 and 1,000,000, inclusive, tests: four
6 thousand nine hundred ten dollars (\$4,910).
- 7 (9) More than 1,000,000 tests: five thousand two hundred sixty
8 dollars (\$5,260) plus three hundred fifty dollars (\$350) for every
9 500,000 tests over 1,000,000, up to a maximum of 15,000,000
10 tests.
- 11 (g) A clinical laboratory performing tests or examinations
12 classified as of moderate or of high complexity under CLIA and
13 a clinical laboratory with a certificate issued under subdivision (c)
14 of Section 1223 shall pay an annual renewal fee based on the
15 number of tests it performed in the preceding calendar year, as
16 follows:
- 17 (1) Less than 2,001 tests: one hundred seventy dollars (\$170).
- 18 (2) Between 2,001 and 10,000, inclusive, tests: seven hundred
19 twenty dollars (\$720).
- 20 (3) Between 10,001 and 25,000, inclusive, tests: one thousand
21 one hundred fifteen dollars (\$1,115).
- 22 (4) Between 25,001 and 50,000, inclusive, tests: one thousand
23 three hundred eighty dollars (\$1,380).
- 24 (5) Between 50,001 and 75,000, inclusive, tests: one thousand
25 seven hundred sixty dollars (\$1,760).
- 26 (6) Between 75,001 and 100,000, inclusive, tests: two thousand
27 forty dollars (\$2,040).
- 28 (7) Between 100,001 and 500,000, inclusive, tests: two thousand
29 four hundred forty dollars (\$2,440).
- 30 (8) Between 500,001 and 1,000,000, inclusive, tests: four
31 thousand six hundred ten dollars (\$4,610).
- 32 (9) More than 1,000,000 tests per year: four thousand nine
33 hundred sixty dollars (\$4,960) plus three hundred fifty dollars
34 (\$350) for every 500,000 tests over 1,000,000, up to a maximum
35 of 15,000,000 tests.
- 36 (h) The application fee for a trainee's license is thirteen dollars
37 (\$13) commencing on July 1, 1983.
- 38 (i) The annual renewal fee for a trainee's license is eight dollars
39 (\$8) commencing on July 1, 1983.

1 (j) The application fee for a duplicate license is five dollars (\$5)
2 commencing on July 1, 1983.

3 (k) The personnel licensing delinquency fee is equal to the
4 annual renewal fee.

5 (l) The director may establish a fee for examinations required
6 under this chapter. The fee shall not exceed the total cost to the
7 department in conducting the examination.

8 (m) A clinical laboratory subject to registration under paragraph
9 (2) of subdivision (a) of Section 1265 and performing only those
10 clinical laboratory tests or examinations considered waived under
11 CLIA shall pay an annual fee of one hundred dollars (\$100). A
12 clinical laboratory subject to registration under paragraph (2) of
13 subdivision (a) of Section 1265 and performing only
14 provider-performed microscopy, as defined under CLIA, shall pay
15 an annual fee of one hundred fifty dollars (\$150). A clinical
16 laboratory performing both waived and provider-performed
17 microscopy shall pay an annual registration fee of one hundred
18 fifty dollars (\$150).

19 (n) The costs of the department in conducting a complaint
20 investigation, imposing sanctions, or conducting a hearing under
21 this chapter shall be paid by the clinical laboratory. The fee shall
22 be no greater than the fee the laboratory would pay under CLIA
23 for the same type of activities and shall not be payable if the
24 clinical laboratory would not be required to pay those fees under
25 CLIA.

26 (o) The state, a district, city, county, city and county, or other
27 political subdivision, or any public officer or body shall be subject
28 to the payment of fees established pursuant to this chapter or
29 regulations adopted thereunder.

30 (p) In addition to the payment of registration or licensure fees,
31 a clinical laboratory located outside the State of California shall
32 reimburse the department for travel and per diem to perform any
33 necessary onsite inspections at the clinical laboratory in order to
34 ensure compliance with this chapter.

35 (q) The department shall establish an application fee and a
36 renewal fee for a medical laboratory technician license, the total
37 fees collected not to exceed the costs of the department for the
38 implementation and operation of the program licensing and
39 regulating medical laboratory technicians pursuant to Section
40 1260.3.

1 (r) The costs of the department to conduct any reinspections to
2 ensure compliance of a laboratory applying for initial licensure
3 shall be paid by the laboratory. This additional cost for each visit
4 shall be equal to the initial application fee and shall be paid by the
5 laboratory prior to issuance of a license. The department shall not
6 charge a reinspection fee if the reinspection is due to error or
7 omission on the part of the department.

8 (s) A fee of twenty-five dollars (\$25) shall be assessed for
9 approval of each additional location authorized by paragraph (2)
10 of subdivision (d) of Section 1265.

11 (t) On or before July 1, 2013, the department shall report to the
12 Legislature during the annual legislative budget hearing process
13 the extent to which the state oversight program meets or exceeds
14 federal oversight standards and the extent to which the federal
15 Department of Health and Human Services is accepting exemption
16 applications and the potential cost to the state for an exemption.